Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APTONASDAQ:AXLANASDAQ:KLTONASDAQ:TTNP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTOAptose Biosciences$4.41$1.35▼$50.10$3.66M1.04227,964 shs650,294 shsAXLAAxcella Health$0.40$0.84$0.34▼$41.25$1.18M0.46267,009 shs6,782 shsKLTOKlotho Neurosciences$0.72-36.3%$0.58$0.11▼$3.91$23.40M0.1631.64 million shs8.15 million shsTTNPTitan Pharmaceuticals$4.30-2.4%$4.37$3.03▼$14.80$3.91M1.3137,863 shs2,166 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTOAptose Biosciences0.00%0.00%0.00%-45.71%-92.49%AXLAAxcella Health0.00%0.00%0.00%0.00%0.00%KLTOKlotho Neurosciences0.00%-53.24%+289.88%+216.53%+72,009,900.00%TTNPTitan Pharmaceuticals0.00%+0.82%-6.75%+21.67%-22.89%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPTOAptose Biosciences1.179 of 5 stars3.80.00.00.00.60.00.0AXLAAxcella HealthN/AN/AN/AN/AN/AN/AN/AN/AKLTOKlotho NeurosciencesN/AN/AN/AN/AN/AN/AN/AN/ATTNPTitan Pharmaceuticals0.3157 of 5 stars0.03.00.00.02.60.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPTOAptose Biosciences 3.50Strong Buy$6.00∞ UpsideAXLAAxcella Health 0.00N/AN/AN/AKLTOKlotho Neurosciences 0.00N/AN/AN/ATTNPTitan Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPTOAptose BiosciencesN/AN/AN/AN/A($0.19) per shareN/AAXLAAxcella HealthN/AN/AN/AN/A$1.42 per shareN/AKLTOKlotho NeurosciencesN/AN/AN/AN/A$0.04 per shareN/ATTNPTitan Pharmaceuticals$180K21.71N/AN/A$2.67 per share1.61Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPTOAptose Biosciences-$51.21M-$89.19N/AN/AN/AN/A-5,683.22%-300.44%N/AAXLAAxcella Health-$81.19M-$19.25N/A∞N/AN/AN/A-259.91%N/AKLTOKlotho Neurosciences-$6.15M-$0.36N/A∞N/AN/A-1,779.01%-275.01%N/ATTNPTitan Pharmaceuticals-$4.71M-$4.59N/A∞N/AN/A-145.92%-129.20%8/13/2025 (Estimated)Latest AXLA, KLTO, APTO, and TTNP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025KLTOKlotho NeurosciencesN/A-$0.08N/A-$0.08N/AN/A5/14/2025Q1 2025TTNPTitan PharmaceuticalsN/A-$0.62N/A-$0.62N/AN/A3/31/2025Q4 2024KLTOKlotho NeurosciencesN/A-$0.07N/A-$0.07N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPTOAptose BiosciencesN/AN/AN/AN/AN/AAXLAAxcella HealthN/AN/AN/AN/AN/AKLTOKlotho NeurosciencesN/AN/AN/AN/AN/ATTNPTitan PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPTOAptose BiosciencesN/A1.051.05AXLAAxcella HealthN/A0.800.80KLTOKlotho NeurosciencesN/A0.290.29TTNPTitan PharmaceuticalsN/A7.737.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPTOAptose Biosciences26.62%AXLAAxcella Health65.07%KLTOKlotho Neurosciences20.07%TTNPTitan Pharmaceuticals31.49%Insider OwnershipCompanyInsider OwnershipAPTOAptose Biosciences1.33%AXLAAxcella Health2.20%KLTOKlotho Neurosciences26.70%TTNPTitan Pharmaceuticals0.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPTOAptose Biosciences312.14 million63.45 millionNo DataAXLAAxcella Health112.95 million2.88 millionOptionableKLTOKlotho NeurosciencesN/A32.49 million23.82 millionN/ATTNPTitan Pharmaceuticals10910,000907,000OptionableAXLA, KLTO, APTO, and TTNP HeadlinesRecent News About These CompaniesTitan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock - MorningstarJune 29 at 6:37 AM | morningstar.comMTitan Pharmaceuticals Completes Private Placement of Series C Convertible Preferred Stock with Blue Harbour Asset Management - NasdaqJune 29 at 6:37 AM | nasdaq.comTitan Pharmaceuticals (NASDAQ:TTNP) Stock Price Passes Above 200 Day Moving Average - Time to Sell?June 28 at 3:49 AM | americanbankingnews.comTitan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred StockJune 27 at 4:18 PM | finance.yahoo.comTitan Pharmaceuticals Completes Private Placement of Series C Convertible Preferred Stock with Blue Harbour Asset ManagementJune 27 at 4:16 PM | quiverquant.comQTitan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred StockJune 27 at 4:05 PM | globenewswire.comtitan pharmaceuticals issues common stock following preferred stock conversionsJune 4, 2025 | investing.comTitan announces filing of registration statement for proposed combinationJune 4, 2025 | finance.yahoo.comTitan Pharmaceuticals, Inc. Files Registration Statement for Proposed Merger with TalenTec Sdn. Bhd.June 3, 2025 | quiverquant.comQTitan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.June 3, 2025 | globenewswire.comTitan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred StockApril 11, 2025 | globenewswire.comTitan Pharmaceuticals: Q4 Earnings SnapshotMarch 20, 2025 | sfgate.comTitan Pharmaceuticals receives Nasdaq notice of non-complianceNovember 27, 2024 | markets.businessinsider.comTitan Pharmaceuticals Faces Nasdaq Compliance Challenges with Reporting and Audit Committee RequirementsNovember 27, 2024 | quiverquant.comQTitan Pharmaceuticals, Inc. Announces Receipt of Notice from NasdaqNovember 27, 2024 | globenewswire.comSanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly BeatOctober 25, 2024 | msn.comTitan Pharmaceuticals, Inc. (TTNP)October 17, 2024 | finance.yahoo.com(TTNP) Technical Pivots with Risk ControlsSeptember 25, 2024 | news.stocktradersdaily.comNWhen (TTNP) Moves Investors should ListenSeptember 15, 2024 | news.stocktradersdaily.comNSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITI, FRZA, TTNP on Behalf of ShareholdersSeptember 9, 2024 | stockhouse.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAXLA, KLTO, APTO, and TTNP Company DescriptionsAptose Biosciences NASDAQ:APTOAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Axcella Health NASDAQ:AXLAAxcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.Klotho Neurosciences NASDAQ:KLTO$0.72 -0.41 (-36.27%) As of 06/27/2025 04:00 PM EasternKlotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.Titan Pharmaceuticals NASDAQ:TTNP$4.30 -0.11 (-2.39%) Closing price 06/27/2025 03:53 PM EasternExtended Trading$12.50 +8.21 (+191.04%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
